Your Authenticated Drugs, Delivered Fast | Rxalldelivered.com
rxscanner.jpg
 In its recent report  on Intelligent drug supply chain Creating value from AI, Delloite feature startups around the world  creating immense value in the drug supply chain around the world
 
Case Study 5 on page 15 of this report documents our work at RxAll in the fight against counterfeit drugs across the world. Here is what Deloitte has to say below

 
 


 
"RxAll, a US-based start-up, has developed an AI-based technology to assure that patients across the world have access to authentic, high-quality drugs. Their platform combines a proprietary molecular sensor (a spectrometer) and a cloud-based DL algorithm, which uses a database of spectral signatures of drugs, to perform non-destructive verification of drugs authenticity.
Their newest device, the RxScanner II, can identify the authenticity and quality of prescription drugs – in tablet, powder or liquid forms – in 20 seconds and with an accuracy of 99.9 per cent.
 
A customised database of drug spectral signatures is built on the RxScanner platform and real-time information about drug quality and locations of where brand counterfeiting is taking place can be seen. This technology can be used by different stakeholders, including hospitals, pharmaceutical companies, pharmacies and regulatory bodies around the world. Their AI system continuously learns from the spectral reads and can rapidly inform pharmaceutical manufacturers about counterfeiting.
 
In 2017, RxAll was selected to participate within the Merck Accelerator Program in Nairobi, Kenya, and, in 2018, was selected to join the Norwegian Katapult Accelerator to help expand their operations.
 
They are currently operating in Canada, China, Ethiopia, Gambia, Ghana, Kenya, Myanmar, Nigeria, Uganda and the US, and plan to expand in Africa, the Americas and Southeast Asia.
 
More recently, RxAll started working with a leading global pharma company with sales operations across 120 countries to enable faster identification of brand counterfeits across problematic spots around the world. RxAll developed a spectral library for the client for a significant brand and the RxScanner was deployed with the client’s drug security team to quickly test suspect brand copies in trouble spots. Importantly, they allowed test results to be connected in real-time to the drug security control centres in the US and the UK.
 
Over a six-month period, RxScanner’s deployment and realtime test reporting to the two control centres reduced reaction time for removing counterfeit copies of this brand off the market from six weeks to two weeks. RxAll is now expanding the library to include more brands facing serious counterfeiting problems"
 

Comments

Contribute

Categories